Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections

Iivo Hetemäki, Saila Laakso, Hannamari Välimaa, Ivvari Kleino, Eliisa Kekäläinen, Outi Mäkitie, T. Petteri Arstila

Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland
Department of Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Institute of Genetics, Helsinki, Finland
Department of Virology, University of Helsinki, Helsinki, Finland
Department of Oral and Maxillofacial Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Department of Molecular Medicine, Karolinska Institutet, Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

**Keywords:**
- AIRE
- Herpes simplex
- Varicella zoster
- Autoantibody
- Immunodeficiency
- Type I interferon

**Abstract**
Almost all patients with autoimmune polyendocrine syndrome type 1 (APS-1) have neutralizing antibodies against type I interferons (IFN), important mediators of antiviral defense. Recently, neutralizing anti-IFN antibodies were shown to be a risk factor of severe COVID-19. Here we show in a cohort of 44 patients with APS-1 that higher titers of neutralizing anti-IFNα4 antibodies are associated with a higher and earlier incidence of VZV reactivation (herpes zoster). The patients also present with uncommonly severe clinical sequelae of herpetic infections. APS-1 patients had decreased humoral immune responses to varicella zoster virus, but cellular responses were comparable to healthy controls. These results suggest that blocking the type I interferon pathway in patients with APS-1 leads to a clinically significant immune deficiency, and susceptibility to herpesviruses should be taken into account when treating patients with APS-1.

**1. Introduction**
Almost all patients with the rare inherited autoimmune polyendocrine syndrome type 1 (APS-1), caused by bi-allelic mutations in the AIRE gene, develop high levels of neutralizing antibodies against type I interferons (IFN), often before any clinical symptoms of autoimmunity [1]. The antibodies have been shown to decrease in vitro the expression of interferon-regulated genes [2]. Recently the anti-IFN antibodies in patients with APS-1 were linked to a markedly increased risk of severe COVID-19 pneumonia [3]. In a child with APS-1 severe COVID-19 disease was successfully treated with plasmapheresis, removing the neutralizing anti-IFN from circulation [4]. It has also been suggested that patients with anti-IFN-ωmga antibodies may have a reduced risk of diabetes [5]. Another family of autoantibodies common in patients with APS-1, neutralizing anti-interleukin-17 and -22 antibodies, has been linked to susceptibility to *C. albicans* infections, one of the hallmarks of APS-1 [7,8].

Type I interferons are important early mediators of antiviral immunity and have also been shown to contribute to the control of latent herpesvirus infections, especially those caused by alphaherpesvirinae herpes simplex virus (HSV) and varicella zoster virus (VZV). Inborn errors in type-I IFN signaling lead to susceptibility to viral infections including fatal HSV encephalitis in a child with IFNAR1 deficiency [9–11]. IFNα has also been used to treat herpes infections [12]. Moreover, in clinical trials of sifalimumab, a monoclonal anti-IFNα antibody, and anifrolumab, a monoclonal anti-IFNα receptor antibody, 5.9% and 7.4%, respectively, of systemic lupus erythematosus patients receiving the treatment experienced herpes zoster due to VZV reactivation [13,14]. In APS-1, only two case reports of severe herpes infections have been published [15,16].

We show that patients with APS-1 are susceptible to a severe clinical course of herpesvirus infections. The patients in our cohort had VZV reactivation already in childhood and adolescence and this was especially common in patients with high titers of anti-IFN antibodies.

**Abbreviations:** APS-1, autoimmune polyendocrine syndrome type 1; IFN, interferon; HSV, herpes simplex virus; VZV, varicella zoster virus.

* Corresponding author: PL 21 (Haartmaninkatu 3), University of Helsinki, Finland.
E-mail address: iivo.hetemaki@helsinki.fi (I. Hetemäki).

https://doi.org/10.1016/j.clim.2021.108851
Received 18 November 2020; Received in revised form 5 September 2021; Accepted 6 September 2021
Available online 8 September 2021
1521-6616/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2. Materials and methods

2.1. Subjects

Patients were identified from the large Finnish cohort of over 90 patients with APS-1 [15]. All living patients (n = 65) with a confirmed diagnosis of APS-1 were invited to participate in the study, 44 (68%) of them consented. The APS-1 diagnosis had been confirmed genetically, by identification of biallelic mutations in AIRE, in all participating patients. The recruitment of the patients has been previously described [17]. The mean age of the 44 patients was 38 years (11–70) and 27 (61%) were women. Blood samples were obtained from 40 patients. The control group for laboratory tests consisted of 46 healthy volunteers (61%) were women. Blood samples were obtained from 40 patients. The incidence and severity of VZV infections was compared with 80 age- and gender-matched healthy control subjects who were recruited for a study on bone health in patients with APS-1 [17]. Their mean age was 40 years (18–71), with a mean age of 38 years (21–70) and 27 (63%) of them were women.

2.2. Clinical data and blood samples

Clinical details were collected from hospital records, through patient interviews, and with a questionnaire including questions about medical history, infections, medications, and other relevant parameters. All patients were clinically examined by a medical doctor (S.L.). Fasting blood samples were collected in the morning between 7 and 10 am after an 8–12-h fast and before morning medications. Sera were isolated with standard protocol and stored at −80 ◦C until analyses.

Table 1

| Patient | Anti-IFNα4 (U) | VZV-IgG (EU) | VZV reactivation | HSV | Unusual HSV | Unusual primary HSV | Hospitalized | Elispot | AIRE genotype | Age group |
|---------|----------------|--------------|------------------|-----|-------------|---------------------|--------------|--------|---------------|-----------|
| 1       | 294            | 110          | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 2       | 195            | 69           | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 3       | 143            | 80           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 4       | 141            | 64           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 5       | 129            | 51           | +                | +   | +           | +                   | HTZ          | 20-29  |               |           |
| 6       | 122            | 37           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 7       | 113            | 86           | +                | +   | +           | +                   | HTZ          | 30-39  |               |           |
| 8       | 112            | 33           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 9       | 109            | 71           | +                | +   | +           | +                   | HMZ          | >60    |               |           |
| 10      | 107            | 100          | +                | +   | +           | +                   | HTZ          | 10-19  |               |           |
| 11      | 103            | 68           | +                | +   | +           | +                   | HMZ          | 20-29  |               |           |
| 12      | 95             | 69           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 13      | 95             | 80           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 14      | 94             | 72           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 15      | 94             | 51           | +                | +   | +           | +                   | HMZ          | <10    |               |           |
| 16      | 94             | 72           | +                | +   | +           | +                   | HMZ          | 20-29  |               |           |
| 17      | 93             | 45           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 18      | 92             | 77           | +                | +   | +           | +                   | HTZ          | 10-19  |               |           |
| 19      | 91             | 51           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 20      | 91             | 85           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 21      | 91             | 47           | +                | +   | +           | +                   | HMZ          | >60    |               |           |
| 22      | 88             | 78           | +                | +   | +           | +                   | HMZ          | >60    |               |           |
| 23      | 88             | 82           | +                | +   | +           | +                   | HTZ          | 20-29  |               |           |
| 24      | 88             | 70           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 25      | 87             | 69           | +                | +   | +           | +                   | HMZ          | 20-29  |               |           |
| 26      | 87             | 84           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 27      | 87             | 71           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 28      | 85             | +            | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 29      | 84             | 95           | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 30      | 84             | 72           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 31      | 83             | 15           | #               | +   | +           | +                   | HTZ          | 10-19  |               |           |
| 32      | 83             | 64           | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 33      | 81             | +            | +                | +   | +           | +                   | HTZ          | 50-59  |               |           |
| 34      | 75             | 58           | +                | +   | +           | +                   | HMZ          | 40-49  |               |           |
| 35      | 73             | 99           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 36      | 66             | 86           | +                | +   | +           | +                   | HMZ          | >60    |               |           |
| 37      | 61             | 99           | +                | +   | +           | +                   | HTZ          | 50-59  |               |           |
| 38      | 53             | 72           | +                | +   | +           | +                   | HTZ          | 50-59  |               |           |
| 39      | 50             | 81           | +                | +   | +           | +                   | HMZ          | 50-59  |               |           |
| 40      | 47             | +            | +                | +   | +           | +                   | HMZ          | 10-19  |               |           |
| 41      | 44             | 56           | +                | +   | +           | +                   | HMZ          | 30-39  |               |           |
| 42      | 41             | 105          | +                | +   | +           | +                   | HTZ          | 20-29  |               |           |
| 43      | 35             | +            | +                | +   | +           | +                   | HTZ          | 10-19  |               |           |
| 44      | 6              | 79           | +                | +   | +           | +                   | HMZ          | 10-19  |               |           |

IFN, interferon; VZV, varicella zoster virus; HSV, herpes simplex virus; HMZ, homozygous for the variant c.769C > T in AIRE; HMZ, compound heterozygous for the variant c.769C > T in AIRE.

# Vaccinated.

a HSV infection with prolonged or atypical symptoms or non-mucosal location.

b VZV primary infection with hospitalization or patient reported severe blistering or high fever.

c Hospitalized either due to VZV primary infection or reactivation or HSV infection.

d Age is given as age group to preserve anonymity.
3.3. Quantification of anti-VZV antibodies

To analyze anti-VZV-IgG-antibodies, polysorp microwell plates (Nunc A/S) were coated with 0.25 µg VZV lytic antigen per well. The antigen was prepared from VZV strain Ellen-infected human fibroblast cell cultures. To minimize non-specific binding, wells were first blocked with PBS containing 1% BSA for 1 h at 37°C. Sera were diluted 1:100 in PBS containing 0.05% Tween 20 and 1% BSA (dilution buffer), added to the wells in duplicate, and incubated for 2 h at 37°C. After incubation, wells were washed three times with PBS containing 0.1% Tween 20 (PBS-T). Horseradish peroxidase (HRP)-conjugated anti-human-IgG (Dako) was then added at a dilution of 1:6000 in dilution buffer and wells were incubated for 1 h at 37°C. After washing three times with PBS-T, 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma-Aldrich) substrate was added and color reaction was stopped after 10 min with 0.5 M H₂SO₄. OD values were measured at 450 nm with a spectrophotometer (Perkin Elmer). Index values were calculated according to the following equation: 

\[
\text{Index} = \left( \frac{(\text{cpm sample} - \text{cpm negative standard})}{\text{cpm positive standard}} \right) \times 100.
\]

2.6. Statistical analysis

Statistical analyses were performed using SPSS version 23 (IBM). Nonparametric Mann–Whitney U test was used to study differences between groups. A p-value of <0.05 was considered significant.

3. Results

3.1. VZV reactivations are prevalent in patients with APS-1 and they have more severe clinical sequelae of herpesvirus infections

Our study included 44 patients with genetically confirmed APS-1, accounting for approximately two-thirds of the currently diagnosed surviving patients in Finland (Table I). Except for one vaccinated patient, all others had had a wild-type primary infection by VZV, requiring hospitalization of three (6.8%) of them (at the age of 1, 3 and 4 years).

More subjectively, an additional 6 patients (13.6%) described their primary infection as unusually severe, with severe blistering and high fever. None of the 80 age and gender-matched healthy controls reported hospitalization or an exceptionally severe primary infection.

Reactivation of VZV as herpes zoster had been experienced by 9 patients with APS-1 (9/44; 20.5%) and by 8 out of 80 control subjects (10.0%). In 3 patients with APS-1 the reactivation had occurred in childhood or adolescence, and in APS-1 patients the median age at VZV reactivation was 30 years (range 1.9–58.0, Fig. 1). One APS-1 patient required hospitalization (Suppl Table I). In the healthy controls, the median age at VZV reactivation was clearly higher at 45 years (range, 27–63, Fig. 1), and none of them had required hospital care.

In the APS-1 group, a clinical HSV infection was reported by 18 patients (40.9%). Seven patients (15.9%) presented with atypical symptoms, nonmucosal manifestations, or prolonged duration. These included one meningitis and one erythema multiforme. Three patients required hospitalization one of whom had also been hospitalized due to primary VZV infection. Among the 80 controls, one (1.3%) had needed prophylactic medication due to recurrent genital HSV infections, and one had a nonmucosal manifestation. None of the controls had required hospitalization due to HSV infection.

3.2. Patients with VZV reactivation or severe herpesvirus infection exhibit high levels of anti-IFNα4 antibodies

We used a radioligand binding assay to measure anti-interferon alpha (anti-IFNα) antibodies in our patients. Anti-IFNα4 was selected as the indicator antibody, since in previous studies it has been the subtype inducing a particularly strong autoantibody formation, and the anti-IFNα4 antibodies also show a good correlation with other anti-IFNα antibodies [19]. At the same time, anti-IFNα4 antibodies show low cross-reactivity with other families of type 1 interferons. Thirty-six of the 40 patients (90%) had detectable levels of serum anti-IFNα4 antibodies, including all 9 patients with a history of VZV reactivation. The patients with a previous VZV reactivation had significantly higher levels

![Graph showing the incidence of VZV reactivation in different age groups in patients with APS-1 (n=44) and in age- and gender-matched healthy controls (n=80).](image-url)
of anti-IFN\textsubscript{\alpha} antibodies than the patients who had not experienced a reactivation (Fig. 2). Of the patients with VZV reactivation, eight exhibited anti-IFN\textsubscript{\alpha} levels above the median and one at the median for the whole APS-1 cohort. Also five out of the six patients hospitalized because of VZV or HSV disease had anti-IFN\textsubscript{\alpha} levels above the median and four out of seven patients with atypical manifestations of HSV had higher and one at the median level of anti-IFN\textsubscript{\alpha} antibodies (Table I).

3.3. Anti-IL-22 antibodies or AIRE genotype are not associated with more severe clinical representation of herpesvirus infection

Autoantibodies to helper T cell-17 cytokines are found in the majority of patients with APS-1 and have been shown to impair antifungal defenses, causing chronic mucocutaneous candidiasis [7,20]. Th17 cytokines are also important for antiviral defense. The majority of patients in the present study (42/44, 95.5%) exhibited anti-IL22 antibodies, but their level did not differ between patient groups with HZ, atypical HSV or patients hospitalized due to herpesvirus infections compared with other patients (data not shown).

Most of our patients (34/44, 77.3%) were homozygous for the pathogenic AIRE variant c.769C > T, p.Arg257Ter. Others had the c.769C > T variant compounded with c.967 979del13, p.Leu323fs (n = 5), c.891C > A (p.Asp297Glu) (n = 2), c.932G > A (p.Cys311Tyr) (n = 2), or c.137C > G (p.Thr46Arg) (n = 1). There was no detectable link between the type of AIRE mutation and the incidence or severity of VZV or HSV infections or reactivations (Table I).

3.4. Patients with APS-1 have reduced anti-VZV antibody levels but normal frequency of VZV reactive T cells

Serum samples were available from 40 of the 44 patients. We used a clinically validated ELISA to measure anti-VZV-IgG antibody levels from these 40 patients with APS-1 and 46 healthy controls. All of our study subjects were VZV-seropositive. The VZV-specific IgG levels were, however, significantly lower in the patients than in the controls (Fig. 3A). VZV IgG levels were similar in patients with and without VZV reactivation (Fig. 3B). PBMC were available from 10 patients and 10 healthy controls and were used to measure the frequency of VZV-reactive T cells. Interferon-\gamma Elispot assay showed that the patients and healthy controls had comparable responses to stimulation with inactivated VZV (Fig. 3C).

4. Discussion

In this study, we show in a cohort of 44 patients with genetically confirmed APS-1 that patients with APS-1 have an increased incidence and unusually early presentation of severe herpesvirus manifestations. The primary VZV infection hospitalization of three (6.8%) patients. In comparison, the hospitalization rate for varicella in the general population prior to the availability of vaccines was estimated to be approximately 6.2 per 10,000 varicella cases (0.06%) [21]. Furthermore, three out of 18 (16.7%) patients with APS-1 with symptomatic HSV infection, normally a self-limiting disease in the general population, required hospitalization. Moreover, reactivation of VZV was seen in patients with APS-1 twice as often as in the controls and at markedly younger age. The disease pattern in patients is in clear contrast with the pattern in the general population, where VZV reactivation is rare in children and adolescents [22].

Increased reactivation of VZV has been observed in patients receiving sirolimus, a recombinant anti-IFN\textsubscript{\alpha} antibody, and notably the reactivation is more common in patients receiving the highest dose of the drug [13]. The same was also true for patients treated with antifrolumab, a monoclonal anti-IFN\textsubscript{\alpha} receptor antibody [14]. Further, an earlier study on patients with APS-1 exhibiting anti-IFN\textsubscript{\alpha} antibodies indicated that the expression level of interferon-stimulated genes in PBMCs ex vivo depended on the titer of neutralizing antibodies in patients’ sera [2]. These findings are consistent with our data showing that the patients with APS-1 with severe clinical representations of herpesvirus infections predominantly had levels of anti-IFN\textsubscript{\alpha} antibodies above the median. Indigenous anti-IFN\textsubscript{\alpha} antibodies have also been associated with severe VZV infection in few patients with RAG deficiency [23] and they have been detected in patients who had developed postherperal neuralgia [24]. Nevertheless, the phenotype of APS-1 is complex, with skewed distribution and function of T cell subsets and autoantibodies to several cytokines.

Our data have some limitations. Our samples were taken after the primary VZV infection or reactivation, and do not necessarily reflect the anti-IFN\textsubscript{\alpha} autoantibody levels at the time of the complications. Because practically all APS-1 patients have high levels of anti-IFN\textsubscript{\alpha} antibodies [1,2,6], it is challenging to distinguish the role they play in the pathogenesis of the disease manifestations. However, anti-IFN\textsubscript{\alpha} autoantibodies are usually the earliest immunopathological manifestation in APS-1, suggesting that our patients already had them at the time of VZV primary infection. Taken together, in our data the anti-IFN\textsubscript{\alpha} antibodies are the factor with the strongest association with severe manifestations of VZV in APS-1 but longitudinal studies would be needed to validate these findings. Also, our findings do not exclude other immunological aberrations contributing to the increased susceptibility.

Indeed, we also found that antibody levels against VZV were significantly lower in the patients compared to controls. Post-vaccination IgG levels against VZV have been shown to correlate with neutralization of the virus, protection against infection, and the clinical representations of VZV breakthrough infections [23]. Passive immunization with anti-VZV immunoglobulin also modifies infection outcome and is used to treat immunocompromised individuals [36]. Thus antibodies to VZV clearly can have a protective role, and the decreased humoral responses in patients with APS-1 may contribute to the more severe course of VZV infection, and perhaps even more to the failure of immunosurveillance to prevent VZV reactivation. On the other hand, the cellular responses to VZV were at least quantitatively normal, although qualitative differences remain a possibility.

Together with previous studies [27], our data highlights the multifaceted immunodeficiency as an important component of APS-1, a
This was also emphasized by the recent demonstration of neutralizing syndrome generally regarded predominantly as an autoimmune disease. I. Hetem anti-IFN antibodies, both in patients with APS-1 and more generally, as a yellow fever virus vaccination [3, 4, 28] risk factor for severe COVID-19 and for life threatening disease after 334812), Novo Nordisk Foundation, Foundation for Pediatric Research Helsinki University research funds, the Helsinki University Doctoral Programme for Rare Diseases and Academy of Finland (grants 334813 and 334812), Novo Nordisk Foundation, Foundation for Pediatric Research and the Swedish Childhood Cancer Foundation. All authors have read the predilection to more severe sequelae in herpesvirus infections should be taken into account when planning the treatment of patients with APS-1, and vaccination or preventive medication should be considered.

Acknowledgements

We would like to thank Olle Kampe for providing the anti-cytokine antibody measurements as well as Nea Boman, Åsa Hallgren and Tamas Bazsinka for their technical assistance. This work was funded by Helsinki University research funds, the Helsinki University Doctoral Programme in Biomedicine, Sigrid Juselius Foundation, European Joint Program for Rare Diseases and Academy of Finland (grants 334813 and 334812), Novo Nordisk Foundation, Foundation for Pediatric Research and the Swedish Childhood Cancer Foundation. All authors have read the journal’s authorship agreement and policy on disclosure of potential conflicts of interest. No conflict of interest to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.clim.2021.108851.

References

[1] A. Meager, K. Viivalingam, P. Peterson, K. Moll, A. Murumagi, K. Krohn, et al., Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1, J. PLoS Med. 3 (7) (2006), e289.
[2] K. Kiszand, M. Link, A.S. Wolff, A. Meager, L. Tsered, T. Org, et al., Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes, Blood. 112 (7) (2008) 2657-2666.
[3] P. Bastard, E. Orlova, L. Soxaeva, R. Levy, A. James, M.M. Schmitt, et al., Preexisting autoantibodies to type 1 IFNs underlie critical COVID-19 pneumonia in patients with APS-1, J. Exp. Med. 218 (7) (2021).
[4] A. Lemaquais, T. Campbell, M. Aranda-Guillén, V. Hennings, P. Brodin, O. Kekki, et al., Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis, J. Allergy Clin. Immunol. 148 (1) (2021) 96-98.
[5] S. Meyer, M. Woodward, C. Hertel, P. Vaiiciu, V. Haase, J. Karner, et al., AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies, Cell. 166 (3) (2016) 582-595.
[6] K. Kiszand, P. Peterson, Autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy: known and novel aspects of the syndrome, Ann. N. Y. Acad. Sci. 1246 (2011) 77-91.
[7] K. Kiszand, A.S. Boe Wolff, K.T. Poulikrajek, L. Tsered, M. Link, K.V. Kiszand, et al., Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines, J. Exp. Med. 207 (2) (2010) 299-308.
[8] A. Puel, R. Doffinger, A. Natividad, M. Chrabieh, G. Barcenas-Morales, C. Picard, et al., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J. Exp. Med. 207 (2) (2010) 291-297.
[9] P. Bastard, J. Mantry, J. Chen, J. Rosain, Y. Seeleuthner, O. Abuzaitan, et al., Herpes simplex encephalitis in a patient with a distinctive form of inherited NARFNI deficiency, J. Clin. Invest. 131 (1) (2021).
[10] I. Meyts, J.L. Casanova, Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway, Eur. J. Immunol. 51 (5) (2021) 1039-1061.
[11] Q. Zhang, P. Bastard, Z. Liu, J. Le Pen, M. Moncada-Velez, J. Chen, et al., Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science 370 (6515) (2020).
[12] D.J. Winston, L.J. Eron, M. Ho, G. Pazin, H. Kessler, J.C. Pottage Jr., et al., Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer, Am. J. Med. 85 (2) (1988) 147-151.
[13] M. Khamashia, J.T. Merrill, V.P. Werth, R. Furie, K. Kalunian, G.G. Illei, et al., Sifalumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study, Ann. Rheum. Dis. 75 (11) (2016) 1909-1916.
[14] R. Furie, M. Khamashia, J.T. Merrill, V.P. Werth, K. Kalunian, P. Broughan, et al., Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus, Rheumatol. (Hoboken, NJ) 69 (2) (2017) 376-386.
[15] A. Batra, S. Davison, S. Rajewal, A. Hale, M.D. Stringer, P. McClean, Varicella recurrence complicated by pneumonia after liver transplantation for APECED, J. Pediatr. Gastroenterol. Nutr. 44 (5) (2007) 637-639.
[16] S. Nagafuchi, K. Umene, F. Yamana, S. Oohashi, M. Shinjo, H. Kurikata, et al., Recurrent herpes simplex virus infection in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1G mutations of the type I IFN alpha/beta receptor gene, J. Infect. Dis. 272 (2010) 605-610.
[17] S. Laakso, J. Borchers, S. Tavniain-Salo, M. Pekkinen, O. Mäkitie, Severe phenotype of APECED (APS1) increases risk for structural bone alterations, Front. Endocrinol. (Lausanne) 11 (2020) 109.
[18] S. Vakkilainen, I. Kileino, J. Honkanen, H. Salo, K. Kauliäluoma, M. Grönbeck, et al., The safety and efficacy of live viral vaccines in patients with cartilage-hair hypoplasia, Front. Immunol. 11 (2020) 2020.
[19] N. Landegren, D. Sharon, E. Freyhult, A. Hallgren, D. Eriksson, P.H. Edqvist, et al., Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1, Sci. Rep. 6 (2016) 2104.
[20] A. Puel, R. Doffinger, A. Natividad, M. Chrabieh, G. Barcenas-Morales, C. Picard, et al., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J. Exp. Med. 207 (2) (2010) 291-297.
[21] A. Bayat, P.D. Burbelo, S.K. Browne, M. Quinlivan, B. Martinez, S.M. Holland, et al., Autoantibodies associated with AIRE deficiency decrease the expression of IFN-α and IFN-γ, J. Exp. Med. 207 (2) (2010) 291-297.
[22] J.G. Liese, V. Grote, E. Rosenfeld, R. Fischer, B.H. Belohradzky, R.V. Kries, The burden of varicella complications before the introduction of routine varicella vaccination in Germany, Pediatr. Infect. Dis. J. 27 (2008) 119-124.
[23] K. Kawai, B.G. Gebremeskel, C.J. Acosta, Systematic review of incidence and complications of herpes zoster: towards a global perspective, BMJ Open 4 (6) (2014), e004833.
[24] J.E. Walters, L.B. Rosen, K. Csomos, J.M. Rosenberg, D. Mathew, M. Kezei, et al., Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency, J. Clin. Invest. 126 (11) (2016) 4389.
[25] M. Khamashia, J.T. Merrill, V.P. Werth, K. Kalunian, P. Broughan, et al., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J. Exp. Med. 207 (2) (2010) 291-297.
[26] M.A. Keller, E.R. Stielheim, Passive immunity in prevention and treatment of infectious diseases, Clin. Microbiol. Rev. 13 (4) (2000) 602-614.

![Fig. 3. Adaptive anti-VZV responses in APS-1 patients. A) VZV-specific IgG levels, shown as enzyme immunoassay units on a relative scale. B) VZV-specific IgG levels in patients without and with VZV reactivation. C) The number of cells producing IFN-γ in healthy controls and APS-1 patients (both with no reactivation and with VZV reactivation) in response to stimulation with inactivated VZV, measured by γ-IFN Elispot. The data are shown as spots per 200,000 cells. Healthy controls are indicated by open circles, APS-1 patients by filled circles. The mean level is indicated by the horizontal bars. The statistical significance of the difference was calculated using the Mann-Whitney U test.](https://doi.org/10.1016/j.clim.2021.108851)
[27] J. Borchers, E. Pukkala, O. Mäkitie, S. Laakso, Patients with APECED have increased early mortality due to endocrine causes, malignancies and infections, J. Clin. Endocrinol. Metab. 105 (6) (2020) e2207–e2213.

[28] P. Bastard, L.B. Rosen, Q. Zhang, E. Michailidis, H.H. Hoffmann, Y. Zhang, et al., Auto-antibodies against type I IFNs in patients with life-threatening COVID-19, Science. (2020) e2207–e2213.

[29] G. Beccuti, L. Ghizzoni, V. Cambria, V. Codullo, P. Sacchi, E. Lovati, et al., A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor, J. Endocrinol. Investig. 43 (8) (2020) 1175–1177.

[30] P. Bastard, E. Michailidis, H.H. Hoffmann, M. Chbihi, T. Le Voyer, J. Rosain, et al., Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine, J. Exp. Med. 218 (4) (2021).